Last reviewed · How we verify

albuterol/salbutamol HFA

Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3 active Small molecule

albuterol/salbutamol HFA is a Beta-2 adrenergic receptor agonist Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc.. It is currently in Phase 3 development for Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD), Prevention of bronchospasm during exercise. Also known as: ProAir HFA, short-acting β2-adrenergic agonists.

Albuterol/salbutamol HFA is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.

Albuterol/salbutamol HFA is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs. Used for Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD), Prevention of bronchospasm during exercise.

At a glance

Generic namealbuterol/salbutamol HFA
Also known asProAir HFA, short-acting β2-adrenergic agonists
SponsorTeva Branded Pharmaceutical Products R&D, Inc.
Drug classBeta-2 adrenergic receptor agonist
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

This medication is a bronchodilator that helps to open up the airways in the lungs, making it easier to breathe. It works by stimulating the beta-2 receptors in the bronchial muscles, causing them to relax and dilate. This results in improved airflow and reduced symptoms of asthma and COPD.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about albuterol/salbutamol HFA

What is albuterol/salbutamol HFA?

albuterol/salbutamol HFA is a Beta-2 adrenergic receptor agonist drug developed by Teva Branded Pharmaceutical Products R&D, Inc., indicated for Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD), Prevention of bronchospasm during exercise.

How does albuterol/salbutamol HFA work?

Albuterol/salbutamol HFA is a short-acting beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.

What is albuterol/salbutamol HFA used for?

albuterol/salbutamol HFA is indicated for Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD), Prevention of bronchospasm during exercise.

Who makes albuterol/salbutamol HFA?

albuterol/salbutamol HFA is developed by Teva Branded Pharmaceutical Products R&D, Inc. (see full Teva Branded Pharmaceutical Products R&D, Inc. pipeline at /company/teva-branded-pharmaceutical-products-r-d-inc).

Is albuterol/salbutamol HFA also known as anything else?

albuterol/salbutamol HFA is also known as ProAir HFA, short-acting β2-adrenergic agonists.

What drug class is albuterol/salbutamol HFA in?

albuterol/salbutamol HFA belongs to the Beta-2 adrenergic receptor agonist class. See all Beta-2 adrenergic receptor agonist drugs at /class/beta-2-adrenergic-receptor-agonist.

What development phase is albuterol/salbutamol HFA in?

albuterol/salbutamol HFA is in Phase 3.

What are the side effects of albuterol/salbutamol HFA?

Common side effects of albuterol/salbutamol HFA include Tremors, Nervousness, Headache, Dizziness, Palpitations.

What does albuterol/salbutamol HFA target?

albuterol/salbutamol HFA targets Beta-2 adrenergic receptor and is a Beta-2 adrenergic receptor agonist.

Related